John Kim
Concepts (280)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Idiopathic Pulmonary Fibrosis | 20 | 2025 | 654 | 3.500 |
Why?
| | Lung Diseases, Interstitial | 14 | 2025 | 636 | 3.410 |
Why?
| | Cardiac Surgical Procedures | 4 | 2022 | 530 | 1.490 |
Why?
| | Cardiopulmonary Bypass | 2 | 2022 | 209 | 1.240 |
Why?
| | Heart Defects, Congenital | 4 | 2021 | 833 | 1.220 |
Why?
| | Sleep Apnea, Obstructive | 3 | 2023 | 291 | 1.140 |
Why?
| | Thrombosis | 2 | 2021 | 366 | 1.000 |
Why?
| | Hemodynamics | 2 | 2021 | 1110 | 0.950 |
Why?
| | Lung | 12 | 2025 | 4062 | 0.850 |
Why?
| | Rheumatic Diseases | 4 | 2024 | 81 | 0.830 |
Why?
| | Pulmonary Fibrosis | 2 | 2024 | 399 | 0.820 |
Why?
| | Pyridones | 2 | 2023 | 168 | 0.800 |
Why?
| | Hernia, Hiatal | 1 | 2023 | 35 | 0.790 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2023 | 139 | 0.760 |
Why?
| | Pseudomonas Infections | 1 | 2023 | 225 | 0.730 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2021 | 82 | 0.710 |
Why?
| | Indoles | 2 | 2023 | 410 | 0.690 |
Why?
| | Tomography, X-Ray Computed | 13 | 2025 | 2667 | 0.690 |
Why?
| | ST Elevation Myocardial Infarction | 1 | 2021 | 54 | 0.680 |
Why?
| | Autoimmune Diseases | 4 | 2024 | 460 | 0.660 |
Why?
| | Resistin | 1 | 2019 | 11 | 0.650 |
Why?
| | Rheumatology | 4 | 2024 | 118 | 0.650 |
Why?
| | Sleep Deprivation | 1 | 2021 | 174 | 0.630 |
Why?
| | Proteomics | 6 | 2025 | 1109 | 0.620 |
Why?
| | Asymptomatic Diseases | 1 | 2019 | 89 | 0.610 |
Why?
| | Biomarkers | 8 | 2025 | 4144 | 0.610 |
Why?
| | Lung Injury | 1 | 2021 | 218 | 0.600 |
Why?
| | Ketorolac | 1 | 2018 | 20 | 0.600 |
Why?
| | Platelet Aggregation | 1 | 2018 | 100 | 0.580 |
Why?
| | Leptin | 1 | 2019 | 236 | 0.570 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2020 | 180 | 0.560 |
Why?
| | Electrocardiography | 1 | 2021 | 629 | 0.560 |
Why?
| | Vital Capacity | 4 | 2023 | 311 | 0.560 |
Why?
| | Adiponectin | 1 | 2019 | 244 | 0.560 |
Why?
| | Humans | 61 | 2025 | 136765 | 0.540 |
Why?
| | Aged | 23 | 2025 | 23794 | 0.510 |
Why?
| | Prospective Studies | 14 | 2025 | 7572 | 0.480 |
Why?
| | Sleep | 1 | 2021 | 753 | 0.470 |
Why?
| | Psychotherapy, Brief | 1 | 2015 | 34 | 0.460 |
Why?
| | Cardiovascular Agents | 1 | 2016 | 159 | 0.440 |
Why?
| | Social Work | 1 | 2015 | 85 | 0.440 |
Why?
| | Male | 33 | 2025 | 67311 | 0.430 |
Why?
| | Tissue Expansion Devices | 1 | 2013 | 5 | 0.420 |
Why?
| | Breast Implants | 1 | 2013 | 19 | 0.400 |
Why?
| | Female | 34 | 2025 | 72795 | 0.400 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 3 | 2011 | 283 | 0.390 |
Why?
| | Free Tissue Flaps | 1 | 2013 | 52 | 0.380 |
Why?
| | Middle Aged | 22 | 2025 | 33228 | 0.370 |
Why?
| | Mammaplasty | 1 | 2013 | 105 | 0.360 |
Why?
| | Critical Care | 1 | 2016 | 583 | 0.350 |
Why?
| | Matrix Metalloproteinase 7 | 2 | 2023 | 26 | 0.340 |
Why?
| | Thrombelastography | 3 | 2020 | 153 | 0.330 |
Why?
| | Genome-Wide Association Study | 4 | 2025 | 1428 | 0.330 |
Why?
| | Disease Progression | 5 | 2025 | 2750 | 0.320 |
Why?
| | Independent Living | 2 | 2021 | 105 | 0.310 |
Why?
| | Venous Thromboembolism | 2 | 2023 | 313 | 0.310 |
Why?
| | Muscle, Skeletal | 6 | 2011 | 1710 | 0.300 |
Why?
| | Postoperative Period | 2 | 2021 | 342 | 0.300 |
Why?
| | Blood Coagulation Disorders | 2 | 2020 | 172 | 0.290 |
Why?
| | Atherosclerosis | 2 | 2025 | 415 | 0.290 |
Why?
| | Hypertension, Pulmonary | 2 | 2016 | 1905 | 0.280 |
Why?
| | Child | 13 | 2023 | 21819 | 0.270 |
Why?
| | Obesity | 1 | 2019 | 2982 | 0.250 |
Why?
| | Oxidants | 1 | 2006 | 111 | 0.240 |
Why?
| | Heart-Assist Devices | 1 | 2021 | 552 | 0.230 |
Why?
| | Antibodies, Antinuclear | 1 | 2025 | 71 | 0.230 |
Why?
| | Cohort Studies | 7 | 2025 | 5701 | 0.230 |
Why?
| | Smoking | 2 | 2025 | 1620 | 0.230 |
Why?
| | Adult | 6 | 2024 | 37631 | 0.220 |
Why?
| | Eicosapentaenoic Acid | 1 | 2023 | 39 | 0.210 |
Why?
| | Smokers | 2 | 2025 | 145 | 0.210 |
Why?
| | Carbon Monoxide | 1 | 2023 | 80 | 0.210 |
Why?
| | Severity of Illness Index | 2 | 2024 | 2822 | 0.200 |
Why?
| | Demography | 1 | 2024 | 291 | 0.200 |
Why?
| | Glucocorticoids | 2 | 2024 | 593 | 0.200 |
Why?
| | Adolescent | 5 | 2021 | 21382 | 0.200 |
Why?
| | Antibody Formation | 1 | 2024 | 298 | 0.190 |
Why?
| | Angiopoietin-2 | 1 | 2022 | 16 | 0.190 |
Why?
| | Methylprednisolone | 1 | 2022 | 85 | 0.190 |
Why?
| | Heart Failure | 2 | 2021 | 2231 | 0.190 |
Why?
| | Insulin | 5 | 2022 | 2406 | 0.190 |
Why?
| | Acetylcysteine | 1 | 2022 | 145 | 0.190 |
Why?
| | Myofibroblasts | 1 | 2023 | 126 | 0.180 |
Why?
| | Tomography | 1 | 2021 | 40 | 0.180 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2022 | 83 | 0.180 |
Why?
| | Respiratory System Abnormalities | 1 | 2021 | 16 | 0.180 |
Why?
| | Blood Loss, Surgical | 1 | 2022 | 100 | 0.180 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 5423 | 0.180 |
Why?
| | Fibrinolytic Agents | 1 | 2023 | 270 | 0.180 |
Why?
| | Actigraphy | 1 | 2021 | 110 | 0.170 |
Why?
| | Treatment Outcome | 4 | 2024 | 10745 | 0.170 |
Why?
| | Proportional Hazards Models | 4 | 2025 | 1261 | 0.170 |
Why?
| | Lung Transplantation | 1 | 2024 | 313 | 0.170 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2234 | 0.170 |
Why?
| | Femoral Vein | 1 | 2020 | 34 | 0.170 |
Why?
| | Arterial Switch Operation | 1 | 2020 | 9 | 0.170 |
Why?
| | Photoplethysmography | 1 | 2020 | 18 | 0.170 |
Why?
| | Heart Diseases | 1 | 2023 | 346 | 0.170 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2021 | 91 | 0.170 |
Why?
| | Proof of Concept Study | 1 | 2020 | 78 | 0.170 |
Why?
| | Vital Signs | 1 | 2020 | 43 | 0.160 |
Why?
| | Body Mass Index | 2 | 2019 | 2375 | 0.160 |
Why?
| | Herniorrhaphy | 1 | 2020 | 60 | 0.160 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2023 | 234 | 0.160 |
Why?
| | Therapy, Computer-Assisted | 1 | 2020 | 62 | 0.160 |
Why?
| | Thorax | 1 | 2020 | 49 | 0.160 |
Why?
| | Antibodies, Viral | 1 | 2024 | 624 | 0.160 |
Why?
| | Coronavirus | 1 | 2020 | 45 | 0.160 |
Why?
| | Pharmaceutical Services | 1 | 2020 | 83 | 0.160 |
Why?
| | Adipokines | 1 | 2019 | 49 | 0.160 |
Why?
| | Child, Preschool | 4 | 2021 | 10997 | 0.160 |
Why?
| | Machine Learning | 1 | 2024 | 487 | 0.150 |
Why?
| | Coronary Angiography | 1 | 2021 | 311 | 0.150 |
Why?
| | Catheterization, Central Venous | 1 | 2020 | 111 | 0.150 |
Why?
| | Arthritis, Rheumatoid | 2 | 2025 | 1167 | 0.150 |
Why?
| | Transcriptome | 2 | 2024 | 969 | 0.150 |
Why?
| | Peritoneal Dialysis | 1 | 2020 | 97 | 0.150 |
Why?
| | Pulmonary Valve | 1 | 2020 | 97 | 0.150 |
Why?
| | Oxidative Stress | 3 | 2011 | 1314 | 0.150 |
Why?
| | Education, Nursing, Continuing | 1 | 2018 | 50 | 0.150 |
Why?
| | Referral and Consultation | 1 | 2024 | 780 | 0.150 |
Why?
| | Length of Stay | 2 | 2021 | 1205 | 0.140 |
Why?
| | Acute Disease | 1 | 2021 | 1006 | 0.140 |
Why?
| | Intensive Care Units, Pediatric | 2 | 2020 | 233 | 0.140 |
Why?
| | Learning Curve | 1 | 2018 | 72 | 0.140 |
Why?
| | Killer Cells, Natural | 1 | 2021 | 443 | 0.140 |
Why?
| | Pulmonary Surfactant-Associated Protein A | 1 | 2017 | 35 | 0.140 |
Why?
| | Hernias, Diaphragmatic, Congenital | 1 | 2020 | 201 | 0.140 |
Why?
| | Ultrasonography, Interventional | 1 | 2018 | 141 | 0.140 |
Why?
| | Circadian Rhythm | 1 | 2021 | 469 | 0.140 |
Why?
| | Glucose | 6 | 2011 | 1019 | 0.140 |
Why?
| | Catheterization, Peripheral | 1 | 2018 | 109 | 0.140 |
Why?
| | Hand | 1 | 2018 | 155 | 0.140 |
Why?
| | Young Adult | 3 | 2021 | 13127 | 0.140 |
Why?
| | Stroke Volume | 1 | 2020 | 612 | 0.130 |
Why?
| | Simulation Training | 1 | 2018 | 99 | 0.130 |
Why?
| | Insulin Receptor Substrate Proteins | 4 | 2011 | 59 | 0.130 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2020 | 291 | 0.130 |
Why?
| | Anti-Bacterial Agents | 2 | 2024 | 1797 | 0.130 |
Why?
| | Polysomnography | 1 | 2017 | 183 | 0.130 |
Why?
| | Cardiac Catheterization | 1 | 2020 | 527 | 0.130 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2024 | 2184 | 0.130 |
Why?
| | Infant, Newborn | 4 | 2023 | 6032 | 0.130 |
Why?
| | Scimitar Syndrome | 1 | 2016 | 9 | 0.130 |
Why?
| | Algorithms | 2 | 2022 | 1689 | 0.130 |
Why?
| | Coronary Care Units | 1 | 2016 | 19 | 0.120 |
Why?
| | Adiposity | 1 | 2021 | 518 | 0.120 |
Why?
| | Rats, Zucker | 4 | 2011 | 35 | 0.120 |
Why?
| | Microbiota | 1 | 2024 | 762 | 0.120 |
Why?
| | Endothelin Receptor Antagonists | 1 | 2016 | 62 | 0.120 |
Why?
| | Nitrous Oxide | 1 | 2016 | 33 | 0.120 |
Why?
| | Hemoptysis | 1 | 2016 | 36 | 0.120 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 2022 | 0.120 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 350 | 0.120 |
Why?
| | Insulin Resistance | 3 | 2011 | 1203 | 0.120 |
Why?
| | Pilot Projects | 1 | 2021 | 1692 | 0.120 |
Why?
| | Vaccination | 1 | 2024 | 1377 | 0.120 |
Why?
| | Linear Models | 1 | 2017 | 846 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 368 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 358 | 0.120 |
Why?
| | Calcium Channel Blockers | 1 | 2016 | 167 | 0.120 |
Why?
| | Acute Kidney Injury | 1 | 2022 | 809 | 0.110 |
Why?
| | Health Status | 1 | 2020 | 788 | 0.110 |
Why?
| | Glycogen Synthase | 4 | 2007 | 7 | 0.110 |
Why?
| | China | 1 | 2015 | 216 | 0.110 |
Why?
| | Antiviral Agents | 1 | 2020 | 739 | 0.110 |
Why?
| | Femoral Neoplasms | 1 | 2014 | 9 | 0.110 |
Why?
| | Muscle Neoplasms | 1 | 2014 | 8 | 0.110 |
Why?
| | Hydrogen Peroxide | 4 | 2011 | 327 | 0.110 |
Why?
| | Fever of Unknown Origin | 1 | 2014 | 12 | 0.110 |
Why?
| | Vasodilator Agents | 1 | 2016 | 331 | 0.110 |
Why?
| | Aging | 1 | 2024 | 1864 | 0.110 |
Why?
| | Hemangioma | 1 | 2014 | 48 | 0.100 |
Why?
| | Motor Activity | 1 | 2018 | 717 | 0.100 |
Why?
| | Wounds and Injuries | 1 | 2020 | 755 | 0.100 |
Why?
| | Scleroderma, Systemic | 2 | 2024 | 122 | 0.100 |
Why?
| | Arthralgia | 1 | 2014 | 56 | 0.100 |
Why?
| | Infant | 4 | 2022 | 9395 | 0.100 |
Why?
| | United States | 4 | 2025 | 14690 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 3 | 2025 | 2412 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1612 | 0.090 |
Why?
| | Systemic Inflammatory Response Syndrome | 2 | 2022 | 93 | 0.090 |
Why?
| | Clinical Competence | 1 | 2018 | 1093 | 0.090 |
Why?
| | Rats | 6 | 2011 | 5639 | 0.080 |
Why?
| | Societies, Medical | 2 | 2024 | 816 | 0.080 |
Why?
| | Risk Factors | 4 | 2025 | 10325 | 0.080 |
Why?
| | Knee Joint | 1 | 2014 | 409 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2020 | 2639 | 0.070 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2007 | 82 | 0.070 |
Why?
| | Anticoagulants | 2 | 2023 | 663 | 0.070 |
Why?
| | Aged, 80 and over | 3 | 2025 | 7585 | 0.070 |
Why?
| | Retrospective Studies | 5 | 2023 | 15504 | 0.070 |
Why?
| | Critical Illness | 2 | 2023 | 804 | 0.060 |
Why?
| | Hypertension | 2 | 2005 | 1284 | 0.060 |
Why?
| | Free Radicals | 1 | 2006 | 110 | 0.060 |
Why?
| | Renin | 1 | 2005 | 35 | 0.060 |
Why?
| | Mass Screening | 2 | 2024 | 1267 | 0.060 |
Why?
| | Tetrazoles | 1 | 2005 | 40 | 0.060 |
Why?
| | Longitudinal Studies | 2 | 2025 | 2829 | 0.060 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2005 | 38 | 0.060 |
Why?
| | Biphenyl Compounds | 1 | 2005 | 63 | 0.060 |
Why?
| | Mixed Connective Tissue Disease | 1 | 2024 | 10 | 0.060 |
Why?
| | Spirometry | 1 | 2025 | 281 | 0.060 |
Why?
| | Sjogren's Syndrome | 1 | 2024 | 54 | 0.050 |
Why?
| | Walk Test | 1 | 2024 | 76 | 0.050 |
Why?
| | Myositis | 1 | 2024 | 52 | 0.050 |
Why?
| | California | 1 | 2025 | 428 | 0.050 |
Why?
| | Mouth | 1 | 2024 | 87 | 0.050 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2023 | 33 | 0.050 |
Why?
| | Vitamin K | 1 | 2023 | 45 | 0.050 |
Why?
| | Forced Expiratory Volume | 1 | 2025 | 531 | 0.050 |
Why?
| | Connective Tissue Diseases | 1 | 2024 | 84 | 0.050 |
Why?
| | Multifactorial Inheritance | 1 | 2025 | 174 | 0.050 |
Why?
| | Proprotein Convertases | 1 | 2023 | 16 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 105 | 0.050 |
Why?
| | Quality Improvement | 1 | 2021 | 1163 | 0.050 |
Why?
| | Serine Endopeptidases | 1 | 2023 | 123 | 0.050 |
Why?
| | Blood Proteins | 1 | 2024 | 252 | 0.050 |
Why?
| | Pulmonary Emphysema | 1 | 2025 | 288 | 0.050 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2022 | 35 | 0.050 |
Why?
| | Osteopontin | 1 | 2022 | 33 | 0.050 |
Why?
| | Respiratory Function Tests | 1 | 2024 | 595 | 0.050 |
Why?
| | Whole Genome Sequencing | 1 | 2023 | 153 | 0.050 |
Why?
| | Europe | 1 | 2023 | 413 | 0.050 |
Why?
| | Metalloproteases | 1 | 2022 | 43 | 0.050 |
Why?
| | Exome | 1 | 2023 | 230 | 0.050 |
Why?
| | Child, Hospitalized | 1 | 2022 | 49 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2024 | 549 | 0.050 |
Why?
| | Anti-Infective Agents | 1 | 2024 | 254 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 308 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2024 | 455 | 0.040 |
Why?
| | Mucin-5B | 1 | 2023 | 224 | 0.040 |
Why?
| | Survival Analysis | 1 | 2024 | 1321 | 0.040 |
Why?
| | Biological Transport | 3 | 2007 | 416 | 0.040 |
Why?
| | Water-Electrolyte Balance | 1 | 2020 | 34 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2024 | 1481 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2024 | 738 | 0.040 |
Why?
| | Genetic Variation | 1 | 2025 | 985 | 0.040 |
Why?
| | Hemorrhage | 1 | 2023 | 721 | 0.040 |
Why?
| | Reference Values | 1 | 2020 | 816 | 0.040 |
Why?
| | Creatinine | 1 | 2020 | 499 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2022 | 901 | 0.040 |
Why?
| | Trauma Centers | 1 | 2020 | 419 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2022 | 1981 | 0.040 |
Why?
| | Gene Expression | 1 | 2023 | 1500 | 0.030 |
Why?
| | Fibroblasts | 1 | 2023 | 993 | 0.030 |
Why?
| | Genotype | 1 | 2022 | 1914 | 0.030 |
Why?
| | Lung Diseases | 1 | 2024 | 768 | 0.030 |
Why?
| | Task Performance and Analysis | 1 | 2018 | 183 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 266 | 0.030 |
Why?
| | Nurse's Role | 1 | 2018 | 152 | 0.030 |
Why?
| | Ultrasonography | 1 | 2020 | 752 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1462 | 0.030 |
Why?
| | Animals | 6 | 2011 | 36847 | 0.030 |
Why?
| | Receptor, Insulin | 2 | 2007 | 105 | 0.030 |
Why?
| | Incidence | 1 | 2022 | 2792 | 0.030 |
Why?
| | Signal Transduction | 2 | 2006 | 5076 | 0.030 |
Why?
| | Prognosis | 1 | 2024 | 4013 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2020 | 800 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2018 | 951 | 0.030 |
Why?
| | Registries | 1 | 2022 | 2015 | 0.030 |
Why?
| | Phosphoproteins | 2 | 2005 | 337 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3189 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 2878 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2011 | 810 | 0.020 |
Why?
| | Glycogen | 1 | 2007 | 55 | 0.020 |
Why?
| | Pyridines | 1 | 2011 | 506 | 0.020 |
Why?
| | Skin Neoplasms | 1 | 2014 | 852 | 0.020 |
Why?
| | Glucose Transporter Type 4 | 1 | 2005 | 40 | 0.020 |
Why?
| | Angiotensin II | 1 | 2005 | 99 | 0.010 |
Why?
| | Oncogene Proteins | 1 | 2005 | 59 | 0.010 |
Why?
| | Protein Kinase Inhibitors | 1 | 2011 | 916 | 0.010 |
Why?
| | Area Under Curve | 1 | 2005 | 314 | 0.010 |
Why?
| | Animals, Genetically Modified | 1 | 2005 | 239 | 0.010 |
Why?
| | Phosphorylation | 1 | 2007 | 1758 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1089 | 0.010 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2005 | 366 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2005 | 437 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2486 | 0.010 |
Why?
| | Mice | 1 | 2005 | 17757 | 0.000 |
Why?
|
|
Kim's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|